Congratulations! I’ve been elected to the Nanobody Quality Management Professional Committee.

  On May 18, 2023, Nabobo Life was honored to attend the establishment conference of the Nanobody Quality Management Professional Committee organized by the China Pharmaceutical Quality Management Association. Ma Chunhui, the general manager of Nabobo Life, was elected as a member of the Nanobody Quality Management Professional Committee of the China Pharmaceutical Quality Management Association.

  In 2022, with the strong support of the Wuhan Municipal Government and the Donghu High-tech Zone Government, Nabao Life established the "Wuhan Nanobody Industry Technology Research and Development Platform". Relying on the Wuhan Institute of Industrial Innovation and Development, it integrated the technical, financial, market operation and resource advantages from multiple aspects such as the Life Science and Technology College of Huazhong University of Science and Technology, Hubei Tianqin Biotechnology Co., Ltd., and Wuhan Aibotek Biotechnology Co., Ltd., and completed the establishment of the company. The mature high-throughput nanobody screening platform is now operating smoothly, and the nanobodies developed for a large number of important antigen targets have achieved remarkable results. Our alpaca experimental base is also gradually expanding, from the initial 100 animals to 600 animals.

       The election of Ma Chunhui, the general manager of Nabao Life, will help the company deeply participate in industry activities, timely understand industry dynamics, and further promote the continuous progress and innovation of Nabao Life's technology in this field. It is known that the Nanobody Quality Management Professional Committee of the China Pharmaceutical Quality Management Association is a branch of the China Pharmaceutical Quality Management Association. It is authorized and entrusted by the national drug supervision and administration department, and participates in formulating industry plans and industry standards, participates in major technological renovations, technology introductions, investment and development projects for preliminary argumentation and other work, aiming to improve the overall level of China's nanobody industry, ensure the safety and effectiveness of nanobody drugs, strengthen industry self-discipline, and regulate the nanobody market. This concept is highly consistent with Nabao's mission of overcoming the "key core technology bottlenecks" in the domestic antibody field, breaking the monopoly of high-quality foreign antibody products, filling the gap in the domestic nanobody industry, and seizing the commanding heights of the global antibody industry with nanobody products, driving the substitution of traditional antibodies in various scientific research and diagnostic fields, and promoting the high-quality development of upstream and downstream products based on nanobody across the country.